Improvement in Temple Hollowing with VYC-20L Hyaluronic Acid Filler: A Multicenter Randomized Controlled Trial of Safety and Effectiveness.

Summary

In a multicenter RCT with 13-month follow-up, VYC-20L significantly improved temple hollowing: 80.4% vs 13.5% responders on the ATHS at month 3 (P<0.0001), with high GAIS responses and FACE-Q improvements. Adverse events were mostly mild, and aesthetic benefits persisted beyond one year.

Key Findings

• At month 3, 80.4% of VYC-20L patients vs 13.5% of controls achieved ≥1-grade ATHS improvement (P<0.0001).
• GAIS responder rates were high by both blinded evaluators (83.8%) and participants (92.9%) at month 3.
• FACE-Q satisfaction scores for facial appearance and temples improved significantly from baseline (both P<0.0001).
• Treatment effects persisted through month 13, with mostly mild, expected adverse events.

Clinical Implications

VYC-20L is an effective option for correcting temple hollowing with durable results and a favorable safety profile; clinicians can expect high satisfaction and should monitor typical mild injection-site reactions.

Limitations

• Sample size and dosing details are not provided in the abstract.
• Comparator was no treatment rather than an active filler; generalizability to other products requires caution.

Future Directions

Head-to-head trials against alternative fillers, anatomical safety mapping for vascular risk reduction, and cost-effectiveness analyses over multi-year horizons.